Spyre Therapeutics, Inc SYRE 深 滬
已收盤 02-06 16:00:00 美东时间
35.12
+2.180
+6.62%
華盛通- 最 高35.21
- 今 開33.77
- 成交量 79.05万股
- 最 低 33.16
- 昨 收 32.94
- 總市值 27.25亿
- 52周最高 35.31
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 10.91
- 委 比 46.32%
- 總股本 7759.21万
- 歷史最高 318.75
- 量 比 1.40
- 振 幅 6.22%
- 歷史最低 2.66
- 每 手 1
- 風險率 6.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
BTIG Reiterates Buy on Spyre Therapeutics, Maintains $70 Price Target
BTIG analyst Julian Harrison reiterates Spyre Therapeutics (NASDAQ:SYRE) with a Buy and maintains $70 price target.
01-16 23:26
Spyre Therapeutics Targets Six Major Trial Results for Inflammatory Disease in 2026
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
01-12 21:08
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Citigroup Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $64
Citigroup analyst Samantha Semenkow initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and announces Price Target of $64.
2025-12-17 23:11
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
2025-12-02 09:50
Jones Trading Upgrades Spyre Therapeutics to Buy, Announces $64 Price Target
Jones Trading analyst Debanjana Chatterjee upgrades Spyre Therapeutics (NASDAQ:SYRE) from Hold to Buy and announces $64 price target.
2025-12-01 21:17
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
<p>Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotech company focused on long-acting antibodies for inflammatory bowel disease and rheumatic diseases, announced that its management will attend three upcoming investor conferences in November 2025. The events include the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, the Stifel 2025 Healthcare Conference in New York, and the Jefferies Global Healthcare Conference i...
2025-10-29 20:05
Spyre Therapeutics Releases New Data From Its Phase 1 Study Of SPY072, An anti-TL1a Antibody For Rheumatic Diseases Showing SPY072 Was Well Tolerated, Maintained Strong Tl1a Suppression, And Supports Quarterly Or Twice-Yearly Dosing
Spyre Therapeutics, Inc. (NASDAQ:SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease ("IBD") and
2025-10-24 20:04
